Dr. Nishi Suryavanshi Receives Award from ACTG Network

Date: 01/07/2022

Congratulations, Nishi Suryavanshi, recipient of ACTG’s Tuberculosis Transformative Science Group Special Contributions Award.

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...